✦ LIBER ✦

PCN68 COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS STANDARD REGIMEN IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND

✍ Scribed by J Walczak; E Gebus; K Lasota; A Semeniuk; D Pawlik; I Malczak; J Lis; M Glasek; G Nogas

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN32 COST-UTILITY ANALYSIS OF DOCETAXEL

✍ J Walczak; D Pawlik; R Wojcik; M Kaczor; J Lis; G Nogas 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

PCN13 COST-EFFECTIVENESS ANALYSIS OF DOC

✍ J Walczak; D Pawlik; R Wojcik; M Kaczor; J Lis; G Nogas 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

PCN13 BUDGET IMPACT ANALYSIS OF THE CONT

✍ J Walczak; E Gebus; K Lasota; A Semeniuk; I Malczak; D Pawlik; J Lis; M Glasek; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

PCN38 COST-EFFECTIVENES ANALYSIS OF DOCE

✍ J Walczak; K Lasota; I Malczak; D Pawlik; A Semeniuk; A Simon; M Bryl; J Lis; G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

PCN82 Cost-Effectiveness Analysis of Tra

✍ Athanasakis, K.; Golna, C.; Kyriopoulos, J. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PCN4 COST-UTILITY ANALYSIS OF FULVESTRAN

✍ J Ryan; M Hirsch; H Knight 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB